Light-to-moderate alcohol consumption is linked to a reduced risk of heart attack, stroke and death among those with heart disease, according to a study published in the journal BMC Medicine on July 26.
The United States Food and Drug Administration approved Bayer’s Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes.
Boehringer Ingelheim and Eli Lilly announced that the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, met the primary endpoint.
The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) for the treatment of heart failure in adults with reduced ejection fraction.
AstraZeneca topped the first annual Pharmaceutical Invention Index, released by IDEA Pharma.
AstraZeneca reported positive results from clinical trial programs for Brilinta and Farxiga, causing stock to jump 3.4 percent.